Enavogliflozin Improves Adipokine Profile in Type 2 Diabetes

August 31, 2025 Victoria Sterling -Business Editor Business

okay, here’s a breakdown of the references provided, formatted for clarity. I’ve extracted the key data from each entry.Reference 42:

Authors: Morciano C, Gugliandolo S, Capece U, Giuseppe G, Mezza T, Ciccarelli G, Soldovieri L, Brunetti M, Avolio A, Splendore A
 Title: SGLT2 Inhibition and adipose tissue metabolism: current outlook and perspectives
Journal: Cardiovasc Diabetol
 Volume: 23
Issue: 1
 Year: 2024
Links:
 PubMed: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660748
Google Scholar: SGLT2 inhibitors in obesity and insulin resistance: focus on fat Browning and macrophage polarization.
Journal: Adipocyte
 Volume: 7
Issue: 2
 Year: 2018
Pages: 121-8
 Links:
CAS: https://cardiab.biomedcentral.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitVaisb0%3D
 PubMed: [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=abstract&list_uids=29376471](

, , , , , , , ,